<DOC>
	<DOCNO>NCT02099825</DOCNO>
	<brief_summary>The purpose research study determine whether take one-time dose combination putatively learning-enhancing medication improve treatment response brief learning-based psychotherapy public speaking anxiety . The two medication ( 1 ) d-cycloserine ( DCS ) , medication agonist ( facilitator ) NMDA glutamatergic receptor show previous study facilitate kind learn memory ; ( 2 ) mifepristone , medication block cortisol , preclinical ( animal ) study show reverse certain kind stress-related learning impairment negative learning . Specifically , investigator goal determine DCS mifepristone take together augment learning occur brief psychotherapy session -- -a public speaking exposure exercise . Evidence learn effect would find participant reduce anxiety subsequent public speaking exposure .</brief_summary>
	<brief_title>Medication Enhanced Rapid Therapy</brief_title>
	<detailed_description>The study total 4 visit , medication give one-time dose one visit ( second visit ) . 1 . During first visit , trained clinical interviewer provide inform consent conduct structure clinical interview . Participants include adult male diagnose social anxiety disorder express fear public speaking , well approximately 10 healthy control participant . Eligible participant ask complete self-report rating social anxiety psychological symptom standard interview anxiety symptom . The experimenter conduct neuropsychological test use measure participant 's cognitive functioning . 2 . At second visit participant administer one-time dosage medication . The participant ask prepare speech within short period time , example exposure therapy . In exposure therapy , people expose situation fear , public speaking , safe control environment . Often people exposure therapy , find situation afraid actually scary seem . The exposure exercise study consist give speech video-recorded . Before exposure exercise , participant provide 250mg DCS 1200mg mifepristone . Participants rate anxiety level negative positive affect speech , well speech . The experimenter conduct neuropsychological test use measure participant 's cognitive functioning . 3 . ( 3 ) &amp; ( 4 ) During next two visit , participant complete second third public speaking exposure exercise identical first , exception NOT receive medication . Participants complete similar battery symptom measure anxiety rating . The investigator look change anxiety rating symptomatology exposure session 1 , exposure session 2 , exposure session 3 .</detailed_description>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<mesh_term>Cycloserine</mesh_term>
	<criteria>For Potential Participants suffer Social Anxiety Disorder Social Phobia : Male least 18 year old current diagnosis Social Anxiety Disorder Social Phobia fear public speaking medically stable good health currently take antidepressant treatment , must stable dose least 8 week Liebowitz Social Anxiety Scale score least 30 Female inability provide inform consent current lifetime diagnosis bipolar disorder , psychotic disorder eat disorder current substance abuse dependence within last 6 month cognitive , sensory , communication problem would prevent completion study severe mental health symptom require immediate treatment ( i.e . active suicidality ) current use medication diagnosis one following : seizure disorder , kidney disease , liver disease current cancer ( history metastatic cancer ) current recent use ( within past 3 month ) systemic corticosteroid diabetic individual untreated unstable endocrinologic disease ( i.e . hyperthyroidism ) lifetime history Cushing 's disease Addison 's disease For Control Group : Male least 18 year old current diagnosis Social Anxiety Disorder Social Phobia report fear public speaking Liebowitz Social Anxiety Scale score equal 29 Female inability provide inform consent current lifetime diagnosis bipolar disorder , psychotic disorder eat disorder current substance abuse dependence within last 6 month cognitive , sensory , communication problem would prevent completion study severe mental health symptom require immediate treatment ( i.e . active suicidality ) current use medication diagnosis one following : seizure disorder , kidney disease , liver disease current cancer ( history metastatic cancer ) current recent use ( within past 3 month ) systemic corticosteroid diabetic individual untreated unstable endocrinologic disease ( i.e . hyperthyroidism ) lifetime history Cushing 's disease Addison 's disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>adult male</keyword>
	<keyword>anxiety</keyword>
	<keyword>public speaking</keyword>
	<keyword>healthy control</keyword>
	<keyword>exposure therapy</keyword>
	<keyword>social anxiety</keyword>
	<keyword>mifepristone</keyword>
	<keyword>d-cycloserine</keyword>
</DOC>